<DOC>
	<DOC>NCT02223260</DOC>
	<brief_summary>The aim of the study is to investigate the safety and tolerability of dabigatran etexilate solution in children aged less than 1 year, to demonstrate comparable PK/PD relationship to older children and adults and to confirm dabigatran etexilate dosing algorithm for children aged less than 1 year.</brief_summary>
	<brief_title>Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children &lt; 1 Year of Age</brief_title>
	<detailed_description>Purpose:</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criteria: Neonates and infants with aged &lt; 12 months at Visit 1 Objective diagnosis of VTE End of planned treatment course with anticoagulant therapy as per standard of care at the investigator site. Written informed consent provided by the patient's parent(s) (or legal guardian) according to local regulations at Visit 1. Exclusion criteria: Weight less than 3 kg at Visit 1 Conditions associated with an increased risk of bleeding renal dysfunction hepatic disease Anemia or thrombocytopenia at screening</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>